<SEC-DOCUMENT>0001214659-20-010017.txt : 20201201
<SEC-HEADER>0001214659-20-010017.hdr.sgml : 20201201
<ACCEPTANCE-DATETIME>20201201065038
ACCESSION NUMBER:		0001214659-20-010017
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20201201
DATE AS OF CHANGE:		20201201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DPW Holdings, Inc.
		CENTRAL INDEX KEY:			0000896493
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTRONIC COMPONENTS, NEC [3679]
		IRS NUMBER:				941721931
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222132
		FILM NUMBER:		201359747

	BUSINESS ADDRESS:	
		STREET 1:		201 SHIPYARD WAY
		STREET 2:		SUITE E
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92663
		BUSINESS PHONE:		(949) 444-5464

	MAIL ADDRESS:	
		STREET 1:		201 SHIPYARD WAY
		STREET 2:		SUITE E
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92663

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIGITAL POWER CORP
		DATE OF NAME CHANGE:	19960823
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>g1130200424b5.htm
<DESCRIPTION>AMENDMENT NO. 1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: right"><B>Registration No. 333-222132</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><B>AMENDMENT NO. 1 DATED DECEMBER 1, 2020 </B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><B>To Prospectus Supplement dated October 2, 2020</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><B>(To Prospectus dated January 11, 2018)</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="dpwlogo_bs.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center; background-color: white"><B>DPW Holdings, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center; background-color: white"><B>Up to $40,000,000</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center; background-color: white"><B>Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>__________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amendment No.&nbsp;1 to Prospectus
Supplement, or this amendment, amends our prospectus supplement dated October 2, 2020, or the prospectus supplement.&nbsp;This
amendment should be read in conjunction with the prospectus supplement and the prospectus dated January 11, 2018, both of which
are to be delivered with this amendment.&nbsp;This amendment amends only those sections of the prospectus supplement listed in
this amendment; all other sections of the prospectus supplement remain as is.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 2, 2020, we entered into
an At-The-Market Issuance Sales Agreement, or the sales agreement, with Ascendiant Capital Markets, LLC, or the sales agent, relating
to the sale of shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and the accompanying
prospectus, as amended by this amendment. In accordance with the terms of the sales agreement, we may offer and sell shares of
our common stock having an aggregate offering price of up to $40,000,000 (which amount includes shares we have already sold pursuant
to the sales agreement prior to the date of this amendment) from time to time through the sales agent. As of November 23, 2020,
we have sold an aggregate of 4,906,340 shares of our common stock pursuant to the sales agreement for gross proceeds of $8,953,354.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our common stock, if any,
under this prospectus supplement will be made by any method permitted that is deemed an &ldquo;at the market offering&rdquo; as
defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or the Securities Act. The sales agent is not required
to sell any specific amount, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading
and sales practices. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is traded on the
NYSE American under the symbol &ldquo;DPW.&rdquo; The sale price of our common stock on November 23, 2020 was $7.19 per share.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of the prospectus
supplement on October 2, 2020, we were subject to General Instruction I.B.6 of Form S-3 as a result of our public float being less
than $75.0 million, which limited the amount of securities we could sell under the registration statement of which the prospectus
supplement forms a part during any 12-month period. As of November 23, 2020, the aggregate market value of our outstanding common
stock held by non-affiliates, or the public float, was $125,143,165, which was calculated based on 17,405,169 shares of our outstanding
common stock held by non-affiliates at a price of $7.19 per share, the closing price of our common stock on that date.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sales agent will be entitled
to compensation at a commission rate of 4% of the gross sales price per share sold. In connection with the sale of the common stock
on our behalf, the sales agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act and the
compensation of the sales agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification
and contribution to the sales agent with respect to certain liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a smaller reporting company
under Rule 405 of the Securities Act and, as such, have elected to comply with certain reduced public company reporting requirements
for this prospectus supplement, the documents incorporated by reference herein and future filings.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>__________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our common stock
involves a high degree of risk. Before buying shares of our common stock, you should carefully consider the risk factors described
in &ldquo;Risk Factors&rdquo; beginning on page&nbsp;S-2 of this amendment and under similar headings in the prospectus supplement
dated October 2, 2020 and other documents incorporated by reference into the prospectus supplement, the accompanying prospectus,
and any free writing prospectus that we have authorized for use in connection with this offering.</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the U.S. Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this
prospectus supplement or the accompanying prospectus is accurate or complete. Any representation to the contrary is a criminal
offense.</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="acmsmaller_logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">The date of this Amendment No. 1 to Prospectus Supplement
is December 1, 2020.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Amendment No. 1 to Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 96%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 4%"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">About this Amendment to Prospectus Supplement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">i</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Special Note Regarding Forward-Looking Information</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">ii</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">The Offering</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">S-1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">S-2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">S-2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Dilution</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">S-2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Plan of Distribution</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">S-4</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Legal Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">S-4</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>We have not, and the sales agent
has not, authorized anyone to provide you with information different than that which is contained in or incorporated by reference
in this amendment, the prospectus supplement, the accompanying prospectus, and in any free writing prospectus that we have authorized
for use in connection with this offering. We are not, and the sales agent is not, making an offer to sell these securities in any
jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this amendment, the
prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this amendment, and in any free
writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective
documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should
read this amendment, the prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this amendment,
and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making
an investment decision. You should also read and consider the information in the documents to which we have referred you in the
sections of the prospectus supplement and the accompanying prospectus titled &ldquo;Where You Can Find More Information&rdquo;
and &ldquo;Incorporation of Certain Documents by Reference.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>For investors outside the United
States: We have not and the sales agent has not done anything that would permit this offering or possession or distribution of
this amendment, the prospectus supplement or the accompanying prospectus in any jurisdiction where action for that purpose is required,
other than in the United States. Persons outside of the United States who come into possession of this amendment or the prospectus
supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering
of the shares of common stock and the distribution of this amendment, the prospectus supplement or the accompanying prospectus
outside of the United States.</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>ABOUT THIS AMENDMENT TO PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This amendment, the prospectus supplement
and the accompanying prospectus are part of a registration statement that we filed with the U.S. Securities and Exchange Commission
(the &ldquo;SEC&rdquo;), using a &ldquo;shelf&rdquo; registration process on Form S-3 (File No. 333-222132), and that was declared
effective by the SEC on January 11, 2018. Under the prospectus supplement dated October 2, 2020, as amended by this amendment,
we may offer shares of our common stock having an aggregate sales price of up to $40.0&nbsp;million (which amount includes the
value of the shares we have already sold prior to the date of this amendment) from time to time at prices and on terms to be determined
by market conditions at the time of offering.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This amendment describes the specific
details regarding this offering, including the price, the amount of our common stock being offered, certain risks of investing
in our common stock and other items. You should read this entire amendment, the prospectus supplement, as well as the accompanying
prospectus, together with the additional information described therein under the headings &ldquo;Incorporation of Certain Documents
by Reference&rdquo; and &ldquo;Where You Can Find More Information&rdquo; carefully before making an investment decision. Generally,
when we refer to this prospectus, we are referring to both parts of this document combined.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent there is a conflict
between the information contained in this amendment, on the one hand, and the information contained in the prospectus supplement
and the accompanying prospectus or in any document incorporated by reference that was filed with the SEC before the date of this
prospectus supplement, on the other hand, you should rely on the information in this amendment. If any statement in one of these
documents is inconsistent with a statement in another document having a later date - for example, a document incorporated by reference
in the accompanying prospectus - the statement in the document having the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should assume that the information
contained in this amendment is accurate as of the date on the front cover of this amendment only and that any information we have
incorporated by reference or included in the accompanying prospectus is accurate only as of the date given in the document incorporated
by reference or as of the date of the prospectus, as applicable, regardless of the time of delivery of this amendment, the prospectus
supplement or the accompanying prospectus or any sale of our common stock. Our business, financial condition, liquidity, results
of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references to &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;company&rdquo; and &ldquo;DPW&rdquo; mean DPW Holdings, Inc., including its subsidiaries,
except where it is clear that the term refers only to DPW Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This amendment, the prospectus supplement,
the accompanying prospectus, and the information incorporated herein and thereby by reference include trademarks, service marks
and tradenames owned by us or other companies. All trademarks, service marks and tradenames included or incorporated by reference
in this amendment, the prospectus supplement or the accompanying prospectus are the property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 27A of the Securities Act
of 1933, as amended, (the &ldquo;Securities Act&rdquo;) and Section 21E of the Securities Exchange Act of 1934, as amended, (the
&ldquo;Exchange Act&rdquo;), provide a &ldquo;safe harbor&rdquo; for forward-looking statements to encourage companies to provide
prospective information about their companies. We intend such forward-looking statements to be covered by the safe harbor provisions
for forward-looking statements contained in the United States Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included or incorporated by reference in this amendment, the prospectus supplement and
the accompanying prospectus regarding our strategy, future operations, financial position, future revenues, projected costs, prospects,
plans and objectives of management, including, without limitation, the discussion of changes and expectations concerning DPW&rsquo;s
business operations during the COVID-19 pandemic, expectations regarding financing, and expectations concerning DPW&rsquo;s business
strategy are forward&#45;looking statements that involve risks and uncertainties. In some cases, you can identify forward-looking
statements by our use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo;
&ldquo;projects&rdquo; &ldquo;believes,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;forecast,&rdquo; &ldquo;potential,&rdquo; &ldquo;thinks,&rdquo; &ldquo;intends,&rdquo; &ldquo;likely,&rdquo; &ldquo;continue,&rdquo;
&ldquo;pursue,&rdquo; &ldquo;strategy&rdquo; or &ldquo;future,&rdquo; or the negative of these words or other words or expressions
of similar meaning. These statements are only predictions. Such statements are based on currently available operating, financial
and competitive information, and are subject to inherent risks, uncertainties and changes in circumstances that are difficult to
predict and many of which are outside of our control. Future events and our actual results and financial condition may differ materially
from those reflected in these forward-looking statements. Therefore, you should not place undue reliance on our forward&#45;looking
statements. There are a number of important factors that could cause our actual results, performance, achievements or industry
to differ materially from those indicated by these forward-looking statements. These important factors include the factors that
we identify under the heading &ldquo;Risk Factors&rdquo; and elsewhere in this amendment, the prospectus supplement and the accompanying
prospectus. Our forward-looking statements are based on our current expectations, intentions and beliefs as of the date of this
amendment or the date of the documents incorporated by reference in this amendment, as the case may be, and except as required
by federal securities laws, we do not undertake, and specifically decline, any obligation to update any of these statements or
to publicly announce the results of any revisions to these statements to reflect future events or developments.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following summary contains
general information about this offering. The summary is not intended to be complete. You should read the full text and more specific
details contained elsewhere in this amendment, the prospectus supplement and the accompanying prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 38%"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Common stock offered by us pursuant to this <BR>
amendment</FONT></TD>
    <TD STYLE="text-align: justify; width: 62%"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Shares of our common stock having an aggregate offering price of up to $40.0 million, which includes approximately $9 million in gross proceeds from the prior sale of common stock under the sales agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Plan of distribution</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Our&nbsp;&ldquo;At the market offering&rdquo; that may be made from time to time on the NYSE American or other market for our common stock in the United States through the sales agent. See the section titled &ldquo;Plan of Distribution&rdquo; on page S-4 of this amendment.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">We intend to use the net proceeds of this offering to finance our growth strategy and for working capital and general corporate purposes. See the section titled &ldquo;Use of Proceeds&rdquo; on page S-2 of this amendment.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">See the section titled &ldquo;Risk Factors&rdquo; beginning on page S-2 of this amendment, page S-5 of the prospectus supplement, and the other information included in, or incorporated by reference into this amendment for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">NYSE American symbol</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">DPW</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: NewSection -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>An investment in our common stock
involves a high degree of risk. You should consider carefully the risks discussed below as well as those described under </I>&ldquo;<I>Risk
Factors</I>&rdquo; <I>of the prospectus supplement and the accompanying prospectus and in the documents we have incorporated by
reference herein and therein. In addition to the following risk factors, you should carefully consider the risks, uncertainties
and assumptions discussed in our Annual Report on Form 10-K/A for the year ended December 31, 2019 and our Quarterly Report on
Form 10-Q for the quarter ended September 30, 2020, and in other documents that we subsequently file with the SEC that update,
supplement or supersede such information, which documents are incorporated by reference into this prospectus. See &ldquo;Where
You Can Find More Information.&rdquo; If any of the events actually occur, our business, financial condition or results of operation
may be materially and adversely affected. In such case, the trading price of our common stock could decline, and investors could
lose all or part of their investment. These risk factors may not identify all risks that we face, and our operations could also
be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. </I></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Additional Risks Related to This Offering</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><B><I>You will experience immediate and substantial dilution.</I></B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offering price per share in this
offering will exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming that
shares of our common stock are sold at a price of approximately $7.19 per share, based on the sale price of our common stock on
the NYSE American on November 23, 2020, for aggregate gross proceeds of $40,000,000, and after deducting commissions and estimated
offering expenses payable by us, you will experience immediate dilution of $5.33 per share, representing the difference between
our as adjusted net tangible book value per share as of September 30, 2020 after giving effect to this offering and the assumed
offering price, net of commissions and offering expenses. The vesting of restricted stock units and the exercise of stock options
and warrants will result in further dilution of your investment. See the section entitled &ldquo;Dilution&rdquo; below for a more
detailed illustration of the dilution you would incur if you participate in this offering.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue and sell shares of our
common stock having aggregate sales proceeds of up to $40,000,000 (which amount includes approximately $9,000,000 of gross proceeds
from shares we have already sold pursuant to the sales agreement prior to the date of this amendment) from time to time. Because
there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions,
expenses, and proceeds to us, if any, are not determinable at this time but will be reported in our periodic reports.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net proceeds,
if any, from this offering for the financing of possible acquisitions of companies and technologies, business expansions and investments
and for working capital and general corporate purposes, which may include the repayment, refinancing, redemption or repurchase
of indebtedness or capital stock. We do not have agreements or commitments for any specific acquisitions at this time, other than
those disclosed in our SEC filings.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount and timing of our actual
expenditures for these purposes may vary significantly and will depend on a number of factors, including our future revenue and
cash generated by operations and other factors described under the heading &ldquo;Risk Factors&rdquo; in this amendment and the
prospectus supplement.&nbsp;&nbsp;Accordingly, our management will have broad discretion in applying the net proceeds of this offering.&nbsp;Pending
these uses, we intend to invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you purchase shares of our common
stock in this offering, you will experience dilution to the extent of the difference between the public offering price per share
in this offering and our as adjusted net tangible book value per share immediately after this offering. Net tangible book value
per share is equal to the amount of our total tangible assets, less our total liabilities, divided by the number of outstanding
shares of our common stock. As of September 30, 2020, our net tangible book value was approximately $(6,559,739), or $(0.57) per
share based on 11,473,410 shares outstanding.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to the sale
of our common stock in the aggregate amount of $40,000,000 at an assumed public offering price of approximately $7.19 per share,
after deducting the underwriting discount and estimated offering expenses payable by us, our as adjusted net tangible book value
as of September 30, 2020 would have been approximately $31,750,261. This represents an immediate increase in net tangible book
value of $2.43 per share to existing stockholders and an immediate decrease of $5.33 per share to new investors purchasing shares
of our common stock in this offering at the public offering price. The following table illustrates this per share dilution:</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 64%">Assumed public offering price per share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">7.19</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-left: 14pt">Net tangible book value per share as of September 30, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.57</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-left: 14pt; padding-bottom: 1pt; text-align: left">Increase in net tangible book value per share after giving effect to this offering</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.43</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">As adjusted net tangible book value per share after giving effect to this offering</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.86</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">Decrease per share to new investors in this offering</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5.33</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing discussion and table
do not take into account further dilution to new investors that could occur upon the exercise of outstanding stock options or warrants
having a per share exercise price less than the per share offering price to the public in this offering. In addition, we may choose
to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for
our current or future operating plans. To the extent that additional capital is raised through the sale of equity or equity-linked
securities, the issuance of these securities could result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table and discussion above are
based on 11,473,410 shares outstanding as of September 30, 2020 and excludes, as of that date, the following:</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">950 shares of our common stock issuable upon the exercise of stock options outstanding as of September
30, 2020, at a weighted average exercise price of $578 per share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">3,588,616 shares of our common stock issuable upon exercise of warrants outstanding as of September
30, 2020, at a weighted average exercise price of $5.91 per share; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">2,232 shares of our common stock reserved for issuance pursuant to the conversion of preferred
stock outstanding as of September 30, 2020.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into a sales agreement,
as amended, with the sales agent, under which we may issue and sell shares of our common stock having an aggregate gross sales
price of up to $40,000,000 from time to time through the sales agent acting as such. Sales of our common stock, if any, under this
prospectus may be made in sales deemed to be &ldquo;at the market offerings&rdquo; as defined in Rule&nbsp;415 under the Securities
Act.&nbsp;The sales agreement was filed as an exhibit to our Current Report on Form&nbsp;8-K filed with the SEC on October 2, 2020,
and the amendment to the sales agreement has been filed as an exhibit to our Current Report on Form 8-K filed with the SEC on December
1, 2020, both of which are incorporated by reference in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each time we wish to issue and sell
common stock, we will notify the sales agent of the number of shares to be issued, the dates on which such sales are anticipated
to be made, any minimum price below which sales may not be made and other sales parameters as we deem appropriate. Once we have
so instructed the sales agent, unless the sales agent declines to accept the terms of the notice, the sales agent has agreed, subject
to the terms and conditions of the sales agreement, to use its commercially reasonable efforts consistent with its normal trading
and sales practices to sell such shares up to the amount specified on such terms. We may instruct the sales agent not to sell shares
of common stock if the sales cannot be effected at or above the price designated by us in any such instruction. We or the sales
agent may suspend the offering of shares of common stock being made through the sales agent under the sales agreement upon proper
notice to the other party.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay the sales agent commissions
for its services in acting as agent in the sale of our common stock. the sales agent will be entitled to compensation at a commission
rate equal to 4% of the aggregate gross sales price of the shares sold. Because there is no minimum offering amount in this offering,
the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also
agreed to reimburse the sales agent for certain specified expenses.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Settlement for sales of common stock
will occur on the second business day following the date on which any sales are made, or on some other date that is agreed upon
by us and the sales agent in connection with a particular transaction, in return for payment of the net proceeds to us. There is
no arrangement for funds to be received in an escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale of the
common stock on our behalf, the sales agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities
Act and the compensation of the sales agent will be deemed to be underwriting commissions or discounts. We have agreed to provide
indemnification and contribution to the sales agent against certain civil liabilities, including liabilities under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offering of our common stock
pursuant to the sales agreement will terminate upon the earlier of (1)&nbsp;the sale of all shares of our common stock having an
aggregate offering price of&nbsp;$40,000,000, inclusive of the up to $8,975,000 already sold thereunder (unless the parties agree
to extend, or increase the amount salable under, the sales agreement)&nbsp;or (2)&nbsp;termination of the sales agreement as permitted
therein. We may terminate the sales agreement at any time upon five days&rsquo; prior notice and the sales agent&nbsp;may terminate
the sales agreement at any time upon ten days&rsquo; prior notice.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed on the
NYSE American under the symbol &ldquo;DPW.&rdquo; The transfer agent of our common stock is Computershare Trust Company, N.A.,
8742 Lucent Blvd., Suite 225, Highlands Ranch, CO 80129.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sales agent and/or its affiliates
may in the future provide various investment banking and other financial services for us for which services they may in the future
receive customary fees.&nbsp;To the extent required by Regulation&nbsp;M promulgated under the Exchange Act, the sales agent&nbsp;will
not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary of the material provisions
of the sales agreement does not purport to be a complete statement of its terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prospectus supplement, as amended
by this amendment, and the accompanying base prospectus in electronic format may be made available on a website maintained by the
sales agent, and the sales agent may distribute this amendment, the prospectus supplement and the accompanying base prospectus
electronically.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Olshan Frome Wolosky LLP, New York,
New York, as our counsel, will pass upon the validity of the common stock offered by this amendment and the prospectus supplement.
Michael Best &amp; Friedrich LLP, Salt Lake City, Utah, is counsel for the sales agent in connection with this offering.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt">S-4</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>acmsmaller_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acmsmaller_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !<&%I;G0N;F5T(#0N,"XU /_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( %0
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MIL^M7=ZES-]JDA:$+S8C,,=/DBG&A"5^=0E"VG+;:[[K3HRJ<6KWZVMLOO\
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M/VB=Y/3X;)WMUN]-%Z&G2^FO]?U^A^LTZ1MX<TXR>;"LVIS^8XD@;R-^GPL
M92I@>3+;-@7@ !@7R3S@ \J1D1XHH$:26>0&5;>&%C)'$YBPLDLEGY:A5^?)
MW=3FOQP^#?[6/BSX>?L6?$BY\3^+O&/Q(_:@;QY^T1#X=\!^(-77Q9XH\%6_
MP\\<>+?">GS^)6O_ +99V$'A[3]!M[;6[^6&&VDUJSU DAMP%+0/C)\<?''[
M+WP _:G\1?%+QOH=KHGB']F=CI5EJ</A#PYXWM?$"^%+7XH>(/&NG:6FG1ZO
MIB7TVM:98-<J^D36MM#-Y3W#R2O@Y))NTNB>C[JRTVWZ>OF(_5;XB_&?X8?"
M?7/"&@>._$UGHVM^.O$L/A3POHK[YM4O]5DV.YAL(G%U]DM8G$UU.ZD00AI)
M&"C-?:'P7GMGCU2.V,$S0WLMO<3V$K75B9(9&! E+RF.0XSL9^"<8[5_.MJ/
MP6_9"_:8_;T^(6O:MX6;7_#/P=^%.I^+-?\ %#ZMJ]IH'B/QMJOBK4]#U3Q9
MH5RM['9C3DB!B@GTDQ[O*"R.Z<5^Y7[&WPM^''P<\!3Z)\+?#T&@^'-3E&N6
MUI;F^G?4TOOWL=\MYJ<US>7$<P</YK3-#D[AQ6L?==-RVE*-GWU6OXG'7I2;
MYDERI=_^'?R[GV[15:.Y201NA!C=B V& .>$ /3<S8'OVJS7KG&5#;?.\BN5
M,@42+N;:=N<. "-LA& 67[P !S@5^=W[27_!,_X _M2_M+?"']J/XEOXG?Q]
M\&-!L_#WA>VTK7-1L-(DL].US5M?M'O;.WNHHYIC?:W>B=RI\R)+=3G97Z.5
M#L;T_E_C2IU*U"SIRDVM'9V=O=T]--O)-@1HH2..,9VQHD:Y9F.U %&68EF.
M!RS$L3R237Q?^V7^PI\!_P!N70?!GAGXZZ#<ZUI_@CQ+!XIT$V>IZAIL]O<P
M- UW 9+&YMR;>_-K8K,CDJ_V49![_:01QG@$<D<_I]*AFBD82>6@#F(!7W $
MMN)V]?E&,<].?K3I2JX?$.M2J23JIQDT]8\W*G?6^W-]X]=OZUL_\ON/R7_:
MH_9.^"/Q6^)?PM\.>.[SP9<7.A>!;3P!X=\!^(_$>H2ZAKGAF2ZEN9=+73UU
M%;S]S)'!!%/8K'?ZCIT5G82331:7%'%R?C3]F']G:YUB[^*GC.P^#6A:OLT[
MX3>)/$FF^.?$?AO3=:3PQ:PZ?I7@#Q=!HWB&QTSQI)X;MH5T'3K/Q?#JUQIF
MF646FJ([.""!/1OC/X$^-W@']J;6_%WPS^'NF^.O#7Q=\.^'/$WB#7-9\,:Y
MXDN/!NN_#BPOM,L-$TZ^M8YM.L&NVN8M3T>(;;J&]N=4FA*_:B3\-:3_ ,$^
M/VA--\6> Y+_ ,?>(KG1_C+\2OAA\>_C.+3PUJ%L/"GQ<N(]4?XB7.ERO:*L
M6GZMIMUHVF31:PTM['/I4D3,HB55]&G1H2@I3JPNU=WDKW=KW3L[K72[O^6L
M:THI)=/RT_.S^\^D?BC\#_V5_%NJ>&/B-XSTW]FG0M1'A2P\!:#JWAOQAJ'@
MG2I_!"-)J>E^%+67P]KNEV5UX6:PU:'4H-(E\VP-OJ@A^SDY%>D:7\!_@S+K
M'P_U?1?"?[/4=]^SI<PGP1:Z3K5S9:=\-+CQQ966N0V^BV"ZJMGIB^+-(OM*
M\3)<I#'<7L>L1RB221F9KG@+]C2P^#>@S?#_ , :/>2>"_"?[1'P<\6>%X-3
MMM2U?4V\/^%OAMX.T?6KB[O;TW#2I>Z[IVIW\RVCBWB^V>3(H*%1\P>/OV7_
M (_>"[?XI>,_"OAO_A,-8^,FMZY\0M<\*VW@;4_+L_%/AGX@>*-4\)PF#1[.
M*:\+>#;GPUX:2XOQ/JDEGHEL+286ZP@-9?0K/F5>$=E9R4;NT9/1]+;ZO:SW
M5G[>ITT^_P N[/KCXH_LT?#WQ+\7/"OQ;^*GPR^ U]\8GM[CPYX0\6>)X9;C
M5KFWCGN=5?1-$AOKM[>\_LN;5+G[,TT,WV*%T$NU@QKP_2OV*_V93X$E^&/A
MGX?_  #G\!?&>&/5],T+2_$FM^3XMB\'?Z1;+H2VVMB1;+0"#=6D.F&./1I)
M)+>R%O%"D:4/VI/A=^TU^U3\$O@C\2]*\)R_"GX__#6[^*GBW1-*;PMKU[)H
M^LYCT[1;*;2;F*>XEFUFWLUFG5HV^W&99H0R.I/F'PS_ &%OBO\ #G0OA=<Z
M7;212_LVE+?P/IESX7U&5M?M-2^(_BSQOK%^+^YMVU>#6=1TGQ)::#J4EM<Q
MPW2:7&2K1D$D,IHS5Y8FDFI<MG4CU?*I*SNTWUMHF[^1[>IW73OTMYKM_ET/
M<+GX.?LR^-/#W@GP/86_[.;Z-\-]6F\/^$]%\+>,+W3/["UKQAJ,VDW^E:3+
MHNN6SW.I^+)$:UOK5WEFU2\>>&\2>X,V:>G?!/\ 93\._&'PS\3](TG]E?1?
MBAX8TW2-&\&26&M6MI/IVE> X8O"/ANRT738M26WLK?18=#A\/V]U;01ZE9I
MIRV\-S&T" ?''C3_ ()K_'*^M_A?HTOB?QEJ]M>?\*MT^/43I.O6M]\'[7PC
M\2=;\2:O:^&VL8X?[.TK4XM0:_CN-1WZI#JMW>W$5PL+PX[+P#\&/VO?@W^T
M;\.)O#O@GQU>_#KPOIEK\$9KGPK:>/-$T/4?!?PV^)GB&T\,^+_%']DS6NDZ
MMKOBOPM%IFK>)]7U9+DZQJ=Y>:A/+*+DNVG]DX2%I2Q%*2U5O:1=[V:MOO9]
MG^+#V\_Z;\O\OQ/J>U\"_LLZ;IWQBN]"T[]D32F^)][KFF_&#7M&U73-%U?Q
MM>:Y$UOK.G^.M:T[4+74-2O;J&5A?SZA<RW5_=R37VI//<W,TK^Q^+OV=O"7
MB3X.VWPJ\5>!_@[+\'%TK0O#JZ+JDNH1:;;:9;06\'A^STU9[X&VLX(UMVTN
M.!DM9#Y=W;H5D5S\A_M>?LL?%[5?"I\4?#KP5+XE\6^&_P!I3XO>._"5OI.E
M>+%\1:':>-=4O1I.HZ3%X>D@^VVE@L\<6IK.D^G3Z=!]FF1@K+7U;\9/ WQF
MU7]E?QQ\(K?PM;>(?&?PIL/AKIWAZ\T?PSJ=GH?Q&O=!\.:%K6KZCHVBZ'#;
MS):-K1O;"*SLXDCB$."@(-85\#A/9-0J4I2DU[O,N96<>BNGJ]=;6N]DT'MY
M]^SW?=?\%^7W'+^)_P!B/X/>,=3\/1>(?A1\#SKGP8\//I6C6FDZAKEE%H?A
MX7,NIV=KK6C:;JL-G<Z9!--]LA@URUN(GG)DVDL<_2'P]@L?B;X$U?1_!?BW
MP;I\L]YIR+J?PM\1WUS9Z-J.FK!C3I3I^H2Q1VL3PA9K&Q\K3)[4%FMWMF(/
MP?J4W[5WC'XBW-]J'P'DT?2OVE?A9X8\!?$34[;PGXT23X?37-I;Z7JM[?SD
M>1&EO 7DW7F=NT*"&%?7G[!OACXJV'A_Q'KGQ5^&'@/X8ZJM_IG@_3[#PEX/
MO/"^H:MI'@[3;;0+37=4U/4X8]9UU-2;35FLFOKJZABL)(;>W"1(B#*MA:/L
M86<&URM)--WLGYVUO\MQ.O-JS=[^OET^7XGO?PH^%OQC\*?$+Q3XI\??%:/Q
M=X9U31=*TS0/"5I;WL%EHUS81P1W%\4N28S-<^4[%XL.6?+D\Y^F***Y3$**
M** "BBB@"C=JK,H90?W<AY&>4&5//=225/8DXZU54GSX5_A<2;U[-B"!_F'0
MG>[MS_$S'J3116J^!>D_PY; /MB9%"O\ZF6[0JWS JMU*BJ0>,*H"@=   .!
M5V8!%8H-I;EBO!) 51G'7"@ >@&***PJ_P 1?("G=JN[=M&[?+)G'/F1Q((W
MS_?0 !6ZJ ,&K<D:--%N16PK8RH.,=,>F.V***R>_P E^2 RY_ENH2.#,8EE
M(X,B[W&US_&N !ALC%3L2MM&RY5F\K+#@G "C)')PH ^@Q116M#^(OZ[#77T
M_5%2]=P;TAV!B2$QD$@QEP Y3^Z6'!QU%6HT5)]J*JK'MCC"@ )&$&$0#[J#
MLHP/:BBNR.R_Z]O_ -)I_P";^]B"3YRT;_,C3HC(W*LC'!5E/!4C@@\$4Z)0
G&8 #"7$2(,<*BN"JKZ*#R . >E%%+K_VXO\ VS_-@:M%%%<P'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>dpwlogo_bs.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 dpwlogo_bs.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI86YE(%EU
M;&\    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,S-P  DI(
M @    ,S-P  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M# P,#/_  !$( &L N0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M]O?X^?K_V@ , P$  A$#$0 _ /U6W^W\Z-_M_.G45]0?)C=_M_.C?[?SIU%
M#=_M_.C?[?SIU% #=_M_.C?[?SIU% #=_M_.C?[?SIU% #=_M_.C?[?SIU%
M#=_M_.C?[?SIU% #=_M_.C?[?SIU% #=_M_.C?[?SIU% #=_M_.C?[?SIU%
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M $8M?2%>3F7Q(]G+/@?J?+/E_P"<"CR_\X%+O'J*-X]17KZGC">7_G H\O\
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MS,E&G[B=WL/UK]M7XQ>(=5N+Z\^*GQ$FNKIS)(X\072!B?15<*/H  *^\?\
M@D1^QY\3_P!M30M0\=?$/XJ?%S3? L$GV72H;+Q1=P3:S.K#S6W,S8@0 H2H
MRS,0"-AKX_\ ^"</["FL?M[_ +1%EX9M_M%GX9TW;>^(M31?^/*T#8VJ>GFR
M'Y$'KENBFOJGXU_\%QO'W[+GQ6USX<?#+0_A3_P@/@BZ;1M#%O:75U&MM#A
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M?ASXG^(M/T'3OA=?:+8ZC/!87$5C=W"30+(0C"0S1EP5 ^;8N[K@ U-\&_\
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M?LJ3U?;HCHRW RJ3]K5V_-G6#@>GH .E%-W^W\Z-_M_.ODSZ8UO W_([:/\
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MTT6OI&O)S+XD>SEGP/U/EK>/44;QZBO?/^%+>&?^@;_Y,2__ !5'_"EO#/\
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M_P#)B7_XJC^T:79_A_F']FU>Z_'_ "/ ]X]11O'J*]\_X4MX9_Z!O_DQ+_\
M%4?\*6\,_P#0-_\ )B7_ .*H_M&EV?X?YA_9M7NOQ_R/&/ SC_A-M'Y'_']#
M_P"C%KZ0KF['X1^'M-O8;B'3]DUNZR1MY\IVL#D'!;'4=ZZ2N#%XB-5IQ/0P
(>'E2BU(__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
